Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Paterson, A. H.
Right arrow Articles by Ashley, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paterson, A. H.
Right arrow Articles by Ashley, S.

Journal of Clinical Oncology, Vol 11, 59-65, Copyright © 1993 by American Society of Clinical Oncology

ARTICLES

Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer

AH Paterson, TJ Powles, JA Kanis, E McCloskey, J Hanson and S Ashley
Department of Medicine, Tom Baker Cancer Center, Calgary, Alberta, Canada.

PURPOSE: Osteolytic metastases often give rise to hypercalcemia, fracture, and bone pain, and occur commonly in patients with recurrent breast cancer. We assessed the bisphosphonate, clodronate, which has proven to be a useful treatment for hypercalcemia and may be a potent inhibitor of tumor-induced osteolysis, for its effect on reducing the osseous complications of metastatic breast cancer. PATIENTS AND METHODS: We studied 173 patients with bone metastases due to breast cancer in a randomized, double-blind, placebo-controlled trial of oral clodronate 1,600 mg/d (85 patients) compared with an identical placebo (88 patients). RESULTS: The patients in each wing were comparable in their clinical, radiologic, and biochemical characteristics at trial entry. In patients who received clodronate, there was a significant reduction compared with placebo in the total number of hypercalcemic episodes (28 v 52; P < .01), in the number of terminal hypercalcemic episodes (seven v 17; P < .05), in the incidence of vertebral fractures (84 v 124 per 100 patient-years; P < .025), and in the rate of vertebral deformity (168 v 252 per 100 patient-years; P < .001). The combined rate of all morbid skeletal events was significantly reduced (218.6 v 304.8 per 100 patient-years; P < .001). Trends were seen in favor of clodronate for nonvertebral fracture rates and radiotherapy requirements for bone pain (particularly spinal pain). No significant survival differences and no significant differences in side effects were observed between the two groups. CONCLUSIONS: These findings indicate that oral clodronate has a beneficial effect on the skeletal morbidity associated with breast cancer and should be considered as antiosteolytic therapy in affected patients. It deserves further investigation as an adjuvant therapy in operable breast cancer and in patients with nonosseous recurrence who are at high risk for bone metastases.


This article has been cited by other articles:


Home page
 Ann OncolHome page
C. I. Ripamonti, M. Maniezzo, T. Campa, E. Fagnoni, C. Brunelli, G. Saibene, C. Bareggi, L. Ascani, and E. Cislaghi
Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan
Ann. Onc., July 22, 2008; (2008) mdn526v1.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Aapro, P. A. Abrahamsson, J. J. Body, R. E. Coleman, R. Colomer, L. Costa, L. Crino, L. Dirix, M. Gnant, J. Gralow, et al.
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
Ann. Onc., March 1, 2008; 19(3): 420 - 432.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
R. Bergner, D. M. Henrich, M. Hoffmann, A. Honecker, G. Mikus, B. Nauth, D. Nagel, and M. Uppenkamp
Renal Safety and Pharmacokinetics of Ibandronate in Multiple Myeloma Patients With or Without Impaired Renal Function
J. Clin. Pharmacol., August 1, 2007; 47(8): 942 - 950.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Gridelli
The Use of Bisphosphonates in Elderly Cancer Patients
Oncologist, January 1, 2007; 12(1): 62 - 71.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J.-J. Body
Breast cancer: bisphosphonate therapy for metastatic bone disease.
Clin. Cancer Res., October 15, 2006; 12(20): 6258s - 6263s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Powles, E. McCroskey, and A. Paterson
Oral bisphosphonates as adjuvant therapy for operable breast cancer.
Clin. Cancer Res., October 15, 2006; 12(20): 6301s - 6304s.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. H.G. Paterson
The Role of Bisphosphonates in Early Breast Cancer
Oncologist, September 1, 2006; 11(suppl_1): 13 - 19.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. Cameron, M. Fallon, and I. Diel
Ibandronate: Its Role in Metastatic Breast Cancer
Oncologist, September 1, 2006; 11(suppl_1): 27 - 33.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Botteman, V. Barghout, J. Stephens, J. Hay, J. Brandman, and M. Aapro
Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases
Ann. Onc., July 1, 2006; 17(7): 1072 - 1082.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
M. Caraglia, D. Santini, M. Marra, B. Vincenzi, G. Tonini, and A. Budillon
Emerging anti-cancer molecular mechanisms of aminobisphosphonates.
Endocr. Relat. Cancer, March 1, 2006; 13(1): 7 - 26.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Clemons, G. Dranitsaris, D. Cole, and M. C. Gainford
Too Much, Too Little, Too Late to Start Again? Assessing the Efficacy of Bisphosphonates in Patients with Bone Metastases from Breast Cancer.
Oncologist, January 1, 2006; 11(3): 227 - 233.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. E. Coleman
Bisphosphonates in breast cancer
Ann. Onc., May 1, 2005; 16(5): 687 - 695.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
M. C Gainford, G. Dranitsaris, and M. Clemons
Recent developments in bisphosphonates for patients with metastatic breast cancer
BMJ, April 2, 2005; 330(7494): 769 - 773.
[Full Text] [PDF]

Home page
 The OncologistHome page
R. E. Coleman
Bisphosphonates: Clinical Experience
Oncologist, September 1, 2004; 9(suppl_4): 14 - 27.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. Conte and V. Guarneri
Safety of Intravenous and Oral Bisphosphonates and Compliance With Dosing Regimens
Oncologist, September 1, 2004; 9(suppl_4): 28 - 37.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. Rizzoli
Bisphosphonates and reduction of skeletal events in patients with bone metastatic breast cancer
Ann. Onc., May 1, 2004; 15(5): 700 - 701.
[Full Text] [PDF]

Home page
 Ann OncolHome page
D. Tripathy, M. Lichinitzer, A. Lazarev, S. A. MacLachlan, J. Apffelstaedt, M. Budde, and B. Bergstrom
Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial
Ann. Onc., May 1, 2004; 15(5): 743 - 750.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
B. Fohr, C. R. Dunstan, and M. J. Seibel
Markers of Bone Remodeling in Metastatic Bone Disease
J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5059 - 5075.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Santini, U. Vespasiani Gentilucci, B. Vincenzi, A. Picardi, F. Vasaturo, A. La Cesa, N. Onori, S. Scarpa, and G. Tonini
The antineoplastic role of bisphosphonates: from basic research to clinical evidence
Ann. Onc., October 1, 2003; 14(10): 1468 - 1476.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J.-J. Body, I. J. Diel, M. R. Lichinitser, E. D. Kreuser, W. Dornoff, V. A. Gorbunova, M. Budde, and B. Bergstrom
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases
Ann. Onc., September 1, 2003; 14(9): 1399 - 1405.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
J R Ross, Y Saunders, P M Edmonds, S Patel, K E Broadley, and S R D Johnston
Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer
BMJ, August 30, 2003; 327(7413): 469.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. Major
The Use of Zoledronic Acid, a Novel, Highly Potent Bisphosphonate, for the Treatment of Hypercalcemia of Malignancy
Oncologist, December 1, 2002; 7(6): 481 - 491.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
J. R Gralow
Bisphosphonates as adjuvant treatment for breast cancer
BMJ, November 9, 2002; 325(7372): 1051 - 1052.
[Full Text] [PDF]

Home page
 JCOHome page
J. R. Berenson, B. E. Hillner, R. A. Kyle, K. Anderson, A. Lipton, G. C. Yee, and J. S. Biermann
American Society of Clinical Oncology Clinical Practice Guidelines: The Role of Bisphosphonates in Multiple Myeloma
J. Clin. Oncol., September 1, 2002; 20(17): 3719 - 3736.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
K. V Haderslev, L. Tjellesen, H. A Sorensen, and M. Staun
Effect of cyclical intravenous clodronate therapy on bone mineral density and markers of bone turnover in patients receiving home parenteral nutrition
Am. J. Clinical Nutrition, August 1, 2002; 76(2): 482 - 488.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Powles, S. Paterson, J. A. Kanis, E. McCloskey, S. Ashley, A. Tidy, K. Rosenqvist, I. Smith, L. Ottestad, S. Legault, et al.
Randomized, Placebo-Controlled Trial of Clodronate in Patients With Primary Operable Breast Cancer
J. Clin. Oncol., August 1, 2002; 20(15): 3219 - 3224.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. L. Sanders, N. Chattopadhyay, O. Kifor, T. Yamaguchi, and E. M. Brown
Ca2+-sensing receptor expression and PTHrP secretion in PC-3 human prostate cancer cells
Am J Physiol Endocrinol Metab, December 1, 2001; 281(6): E1267 - E1274.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
R. J. Cook and P. Major
Methodology for Treatment Evaluation in Patients With Cancer Metastatic to Bone
J Natl Cancer Inst, April 4, 2001; 93(7): 534 - 538.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. R. Berenson, R. A. Vescio, L. S. Rosen, J. M. VonTeichert, M. Woo, R. Swift, A. Savage, E. Givant, M. Hupkes, H. Harvey, et al.
A Phase I Dose-ranging Trial of Monthly Infusions of Zoledronic Acid for the Treatment of Osteolytic Bone Metastases
Clin. Cancer Res., March 1, 2001; 7(3): 478 - 485.
[Abstract] [Full Text]

Home page
 JCOHome page
T. Saarto, C. Blomqvist, P. Virkkunen, and I. Elomaa
Adjuvant Clodronate Treatment Does Not Reduce the Frequency of Skeletal Metastases in Node-Positive Breast Cancer Patients: 5-Year Results of a Randomized Controlled Trial
J. Clin. Oncol., January 1, 2001; 19(1): 10 - 17.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. L. Sanders, N. Chattopadhyay, O. Kifor, T. Yamaguchi, R. R. Butters, and E. M. Brown
Extracellular Calcium-Sensing Receptor Expression and Its Potential Role in Regulating Parathyroid Hormone-Related Peptide Secretion in Human Breast Cancer Cell Lines
Endocrinology, December 1, 2000; 141(12): 4357 - 4364.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. E. Coleman
Management of Bone Metastases
Oncologist, December 1, 2000; 5(6): 463 - 470.
[Abstract] [Full Text]

Home page
 Palliat MedHome page
K. Mannix, S. H. Ahmedzai, H. Anderson, M. Bennett, M. Lloyd-Williams, and A. Wilcock
Using bisphosphonates to control the pain of bone metastases: evidence-based guidelines for palliative care
Palliative Medicine, September 1, 2000; 14(6): 455 - 461.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
K. El Abdaimi, N. Dion, V. Papavasiliou, P.-E. Cardinal, L. Binderup, D. Goltzman, L.-G. Ste-Marie, and R. Kremer
The Vitamin D Analogue EB 1089 Prevents Skeletal Metastasis and Prolongs Survival Time in Nude Mice Transplanted with Human Breast Cancer Cells
Cancer Res., August 1, 2000; 60(16): 4412 - 4418.
[Abstract] [Full Text]

Home page
 JCOHome page
B. E. Hillner, J. N. Ingle, J. R. Berenson, N. A. Janjan, K. S. Albain, A. Lipton, G. Yee, J. S. Biermann, R. T. Chlebowski, and D. G. Pfister
American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer
J. Clin. Oncol., March 13, 2000; 18(6): 1378 - 1391.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. L. Theriault, A. Lipton, G. N. Hortobagyi, R. Leff, S. Gluck, J. F. Stewart, S. Costello, I. Kennedy, J. Simeone, J. J. Seaman, et al.
Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled Trial
J. Clin. Oncol., March 1, 1999; 17(3): 846 - 846.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
I. J. Diel, E.-F. Solomayer, S. D. Costa, C. Gollan, R. Goerner, D. Wallwiener, M. Kaufmann, and G. Bastert
Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment
N. Engl. J. Med., August 6, 1998; 339(6): 357 - 363.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
P. Magnusson, L. Larsson, G. Englund, B. Larsson, P. Strang, and L. Selin-Sjogren
Differences of bone alkaline phosphatase isoforms in metastatic bone disease and discrepant effects of clodronate on different skeletal sites indicated by the location of pain
Clin. Chem., August 1, 1998; 44(8): 1621 - 1628.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
T. A. Guise and G. R. Mundy
Cancer and Bone
Endocr. Rev., February 1, 1998; 19(1): 18 - 54.
[Abstract] [Full Text]

Home page
 Endocr. Rev.Home page
H. Fleisch
Bisphosphonates: Mechanisms of Action
Endocr. Rev., February 1, 1998; 19(1): 80 - 100.
[Abstract] [Full Text]

Home page
 JBJSHome page
A. D. AARON
Current Concepts Review - Treatment of Metastatic Adenocarcinoma of the Pelvis and the Extremities
J. Bone Joint Surg. Am., June 1, 1997; 79(6): 917 - 32.
[Full Text]

Home page
 NEJMHome page
P. D. Delmas
Bisphosphonates in the Treatment of Bone Diseases
N. Engl. J. Med., December 12, 1996; 335(24): 1836 - 1837.
[Full Text]

Home page
 BMJHome page
J. A Kanis and E. V McCloskey
Events per person year
BMJ, June 3, 1995; 310(6992): 1469a - 1469.
[Full Text]

Home page
 BMJHome page
C L Davis and J R Hardy
Current Issues in Cancer Palliative care
BMJ, May 21, 1994; 308(6940): 1359 - 62.
[Full Text]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1993 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online